Palvella Therapeutics (PVLA) Other Operating Expenses (2013 - 2023)
Palvella Therapeutics (PVLA) posted quarterly Other Operating Expenses of $1.7 million for Q4 2024, up 111.2% year-over-year from $789773.1 in Q1 2024, and up 393.66% quarter-over-quarter from -$568000.0 in Q3 2024.
Powered by 
Analysis
Palvella Therapeutics (PVLA) Other Operating Expenses (2013 - 2023) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Other Operating Expenses for 3 consecutive years, with $1.7 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Other Operating Expenses rose 111.2% year-over-year to $1.7 million; the TTM figure through Sep 2025 stood at $1.7 million (up 110.79% YoY), while the FY2024 annual figure was $1.1 million, down 95.24% from the prior year.
- Other Operating Expenses rose to $1.7 million in Q4 2024 per PVLA's latest filing, from -$568000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $14.9 million in Q3 2023 and bottomed at -$14.9 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -14.89 Mn |
| Sep 30, 2023 | 14.89 Mn |
| Dec 31, 2013 | 7,912.00 |
| Sep 30, 2013 | 5,750.00 |